Samith Kochuparambil, MD
Hematology & Oncology · Minneapolis, MNNPI 1548490329
Payments from drug & device makers
Across 797 payments — averaging $4101.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1.7M
- Merck$557K
- Genentech, Inc.$503K
- Mirati Therapeutics, Inc.$301K
- EMD Serono, Inc.$97K
- Janssen Research & Development, LLC$79K
- plus $74K from 12 others
What the payments were for
- Consulting fees$1,23856%
- Speaking & faculty fees$73133%
- Grants$1205%
- Food & beverage$994%
- Education$261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 53 | $1,657,292 |
| Merck | 449 | $557,476 |
| Genentech, Inc. | 42 | $503,243 |
| Mirati Therapeutics, Inc. | 6 | $301,005 |
| EMD Serono, Inc. | 73 | $97,194 |
| Janssen Research & Development, LLC | 141 | $78,664 |
| AstraZeneca | 5 | $22,939 |
| Eli Lilly | 9 | $20,302 |
| Astrazeneca UK Limited | 3 | $18,000 |
| Clovis Oncology, Inc. | 5 | $5,096 |
| Boston Scientific | 2 | $3,000 |
| Biocompatibles UK Ltd | 1 | $2,400 |
| Beigene USA, Inc. | 2 | $1,287 |
| Genmab U.S., Inc. | 2 | $734 |
| Ares Trading SA | 1 | $392 |
| AbbVie | 1 | $120 |
| Blueprint Medicines Corporation | 1 | $48 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$1,238
- EPKINLY$731
- NATRELLE SALINE-FILLED BREAST IMPLANTS$120
- REVOLVE$120
How this compares
$3,269,204 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 48 | $1,186,034 |
| Lenalidomide | 39 | $481,178 |
| XtandiEnzalutamide | 21 | $305,070 |
| RevlimidLenalidomide | 16 | $258,474 |
| BrukinsaZanubrutinib | 23 | $245,693 |
| CalquenceAcalabrutinib Maleate | 19 | $217,820 |
| TagrissoOsimertinib Mesylate | 13 | $210,600 |
| RubracaRucaparib Camsylate | 12 | $150,083 |
| GilotrifAfatinib Dimaleate | 12 | $133,542 |
| Abiraterone Acetate | 86 | $97,066 |
| VenclextaVenetoclax | 13 | $89,396 |
| EliquisApixaban | 22 | $15,871 |
| XareltoRivaroxaban | 13 | $7,203 |
| Dexamethasone | 68 | $1,163 |
| Hydroxyurea | 49 | $916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $22,939 | $428,42032 claims |
| Beigene USA, Inc.Brukinsa | $1,287 | $245,69323 claims |
| Clovis Oncology, Inc.Rubraca | $5,096 | $150,08312 claims |
| AbbVieVenclexta | $120 | $89,39613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Other hematology & oncology in Minneapolis
- Shilpa GuptaMinneapolis$16.3M
- Timothy LarsonMinneapolis$7.2M
- Veronika BachanovaMinneapolis$2.6M
- Douglas YeeMinneapolis$2.6M
- Amit KulkarniMinneapolis$2.5M
- Nicholas ZorkoMinneapolis$2.5M
- Arpit RaoMinneapolis$1.6M
- Daniel OlearyMinneapolis$1.5M
- Mark RedingMinneapolis$1.3M
- Gautam JhaMinneapolis$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.